NeurologyLive® Friday 5 — November 13, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Don’t have time to read or watch a full video interview? Click here to check out our shorts!

Click the read more or watch now buttons for more details and information about each highlight.

1: How Asundexian’s Approval Could Reshape Antithrombotic Therapy in Noncardioembolic Stroke: Mike Sharma, MD, MSc

In a recent video interview, Mike Sharma, MD, MSc, professor of medicine and neurology at McMaster University, discussed the FDA approval of asundexian, why secondary prevention of noncardioembolic stroke has lagged behind, and the phase 3 OCEANIC-STROKE trial. [WATCH TIME: 5 minutes]

2: Understanding the Long-Term Effects of Traumatic Brain Injury in Military Personnel: Clayton Mucha, MD

In a recent Q&A interview, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel, in honor of Veterans Day, held annually on November 11th.

3: The Evolving Role of Patient Advocacy in Neuromuscular Research and Care: Paul Melmeyer, MPP

In a recent video interview, Paul Melmeyer, MPP, executive vice president of public policy and advocacy at the Muscular Dystrophy Association, discusses NMAC's transition toward year-round collaboration and its role in advancing neuromuscular research, treatment access, and care. [WATCH TIME: 3 minutes]

4: Recapping MDS 2026: Biomarkers, Aging, and Prodromal Movement Disorders

In a recent Q&A interview, Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.

5: Understanding the Role of TAPS Therapy in Essential Tremor Management: Stuart H. Isaacson, MD, FAAN

In a recent video interview, Stuart H. Isaacson, MD, FAAN, director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton, discussed a recent analysis of the PROSPECT trial of using transcutaneous afferent patterned stimulation in essential tremor. [WATCH TIME: 5 minutes]